Playbook is likely to be adopted by other countries, shaping markets
Get the latest international news and world events from around the world.
AI Cybersecurity Access Tiers: Who Gets The Best AI?
OpenAI’s new Daybreak Red tier gives approved defenders a model that completes 95% of advanced exploit-development requests, versus roughly 2% for the public version of the same base model. That gap is now the real story: AI cybersecurity access tiers decide who gets frontier defensive power and who doesn’t, and access runs through a partner list, not a price tag.
AI cybersecurity access tiers stopped being a theoretical debate this month. OpenAI expanded its Daybreak program into two levels, Blue and Red, and released GPT-5.6-Cyber, a specialized model built specifically for vulnerability research and exploit-chain development, according to SecurityBrief’s coverage of the launch. In an internal OpenAI evaluation, the new model completed 95.0% of advanced cyber requests covering authentication bypass, privilege escalation, and exploit-chain development, compared with 1.5% for the general-release model and 2.0% for that same model through the safeguarded Daybreak Blue tier.
GPT-5.6-Cyber is only available through Daybreak Red, gated behind identity verification, monitoring, legal attestations, and approved-use restrictions, per Cyberpress’s reporting. Under OpenAI’s own Preparedness Framework, the model was rated “High” for cybersecurity capability, one step below the “Critical” threshold that recently triggered an internal suspension of a different unreleased model, Astra, on August 7. These AI cybersecurity access tiers exist because the underlying capability is real: a general-purpose model built to refuse exploit-writing requests is far less useful to a security team validating a patch than one built to complete them.
Miniaturized Laser System Enables Record Flux in Microgravity
Scientists produce atomic quantum gas mixtures with unprecedented particle flux to test fundamental physics in space.
Maker compresses a 2.9MB song by 1000x and prints it on paper as eight QR codes is two minutes long, requires a neural network for playback
Meta’s AI codec was used for the compression.
They Injected a Human With “Youth Genes” — Here’s What Actually Happened
The first human trial of a therapy designed to make older cells behave more like younger ones has begun. But did it reverse aging? No result has been reported yet.
In this video, Dr Deepa explains what was actually injected, why researchers started with only one eye, how ER-100 uses partial epigenetic reprogramming, and what this Phase 1 trial is really designed to discover.
We also examine a separate Klotho gene therapy being promoted through overseas clinics. What evidence supports it? Why don’t promising animal studies prove that people will live longer? And what risks should anyone understand before considering an experimental anti-aging treatment?
Covered in this video:
• ER-100 and partial epigenetic reprogramming.
• OSK and the Yamanaka factors.
• Why the treatment was injected into one eye.
• The doxycycline activation system.
• What researchers are monitoring for five years.
• Klotho and Minicircle gene therapy.
• Regulated trials versus treatments offered overseas.
• Tumour, immune and manufacturing risks.
• Questions to ask before considering experimental treatment.
The first participant was dosed in a Phase 1 study involving ER-100 for open-angle glaucoma and NAION. The primary purpose is to evaluate safety and tolerability—not to prove that human aging has been reversed.
#reverseaging #genetherapy #longevity.
